Product Overview

Idelalisib, marketed under the brand name Ideenat, is an oral medication used in the treatment of certain types of blood cancers, specifically chronic lymphocytic leukemia (CLL) and follicular lymphoma. It functions as a selective inhibitor of phosphatidylinositol 3-kinase (PI3K), which plays a crucial role in the survival and proliferation of malignant B-cells.

Mechanism of Action

Idelalisib selectively targets the delta isoform of the PI3K pathway, leading to the inhibition of B-cell receptor signaling. This results in decreased cell proliferation and survival, ultimately promoting cancer cell death.

Indications

Idelalisib is indicated for the treatment of:

• Chronic lymphocytic leukemia (CLL) in combination with rituximab.
• Follicular lymphoma that is refractory to two or more prior systemic therapies.

Dosage and Administration

The recommended dosage of Idelalisib is typically 150 mg taken orally twice daily. It is important to follow the prescribing physician's instructions and to not exceed the recommended dosage.

Side Effects

Common side effects may include:

• Diarrhea
• Fatigue
• Abdominal pain
• Fever

Serious side effects can occur, including liver issues, severe infections, and intestinal perforation. Patients should be monitored regularly during treatment.

Drug Interactions

Idelalisib may interact with other medications, so it is vital to inform healthcare providers of all medications being taken, including over-the-counter drugs and supplements.

Storage Instructions

Store Idelalisib at room temperature, away from moisture and heat. Keep out of reach of children.

Conclusion

Idelalisib (Ideenat) offers a targeted therapy option for patients with specific types of blood cancers. Its unique mechanism of action and selective targeting of cancer cells make it a valuable addition to cancer treatment regimens. Always consult with a healthcare provider for personalized medical advice and treatment plans.